First and Only In-Home Rapid Oral HIV Test Now Available to Consumers Across the U.S.
09 10월 2012 - 8:00PM
A Major Breakthrough in the Fight Against HIV
– the OraQuick® In-Home HIV Test Now Can Be
Purchased at Retailers Nationwide and Online
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the
availability of the OraQuick® In-Home HIV Test at retailers
nationwide and online, making it the first rapid infectious disease
test ever to be made available directly to consumers for in-home
use. To mark the launch, the Company is collaborating with a high
profile celebrity as part of an ongoing awareness campaign on the
importance of knowing your HIV status. Details on the campaign will
be shared on a national media webcast on Wednesday, October 10th at
3 p.m. ET.
"For the first time ever, individuals now have access to an
in-home rapid oral HIV test – the same test healthcare
professionals have used and trusted for years – that will empower
them to learn their HIV status in the comfort and privacy of their
own home," said Douglas A. Michels, President and Chief Executive
Officer of OraSure Technologies. "This is a tremendous breakthrough
in our fight against HIV and AIDS."
The OraQuick® In-Home HIV Test detects antibodies to both HIV-1
and HIV-2 with an oral swab, providing a confidential in-home
testing option with results in as little as 20 minutes. The in-home
test is an over-the-counter version of OraQuick ADVANCE®, an oral
swab rapid test with more than 25 million units sold in the
professional market, including doctors, hospitals, clinics and
other trained professionals. The OraQuick In-Home HIV Test is now
available nationwide at more than 30,000 retailers and online and
at OraQuick.com.
To ensure optimal support for individuals using the OraQuick®
In-Home HIV Test, OraSure is making available specialized resources
including live support and comprehensive referral services 24 hours
a day, seven days a week, every day of the year, through a
toll-free support center and comprehensive consumer website. The
OraQuick® Support Center is staffed with highly trained, bi-lingual
(English/Spanish) representatives who are available by telephone at
866-436-6527 to answer questions about HIV/AIDS and using and
interpreting the test. They also provide referrals to follow-up and
care, and they can also take orders for the OraQuick In-Home HIV
Test. Additionally, the product website provides access to
resources and referral to follow-up counseling, confirmatory
testing and medical care.
Visit OraQuick.com for more information.
National Media Webcast
OraSure Technologies will hold a national media webcast to share
details on the campaign on Wednesday, October 10 at 3 p.m. Eastern
Time. The webcast is intended for media only. To attend the
webcast, please log on here five minutes ahead of the Webcast. The
meeting number is 596 724 325 and the password is orasure. For
audio only, media can use the toll-free line 1-877-481-4772 and
enter the conference code 39605844 to join the
meeting.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of oral fluid diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its innovative products include rapid tests for
the detection of antibodies to HIV and HCV at the point of care and
testing solutions for detecting various drugs of abuse. In July
2012, the Company received approval from the U.S. Food and Drug
Administration for the Company's OraQuick® In-Home HIV Test for
sale directly to consumers in the over-the-counter (OTC) market –
making it the first and only rapid OTC HIV test approved in the
U.S. In addition, the Company is a leading provider of oral fluid
sample collection, stabilization and preparation products for
molecular diagnostic applications. OraSure's portfolio of products
is sold globally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their
health.
For more information on OraSure Technologies, please visit
www.orasure.com.
The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440
CONTACT: Investor Contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
investorinfo@orasure.com
Media Contact:
Ashley Buford
GolinHarris for OraSure Technologies
917-653-5694
abuford@golinharris.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024